Already Registered? Log In Now Not Registered?
Complete this form to enter the webcast. Already Registered?

(* indicates required field)

Complete this form to enter the webcast.
(* indicates required field)



*Denotes required.


Lipid-Based Drug Delivery of Cannabinoids

This event is now available on demand.

Event Overview:
 
While per-oral delivery is the patient-preferred route of administration, the per-oral dosing of cannabinoid actives is not trivial.  Due to low solubility and extensive first pass metabolism, the per-oral dosing of cannabinoid actives often results in relatively low bioavailability.  Lipid-based drug delivery, including self-emulsifying drug delivery, readily provides for improved per-oral solubility and bioavailability of cannabinoid actives, increasing the therapeutic effectiveness of these products.

Key Learning Objectives:
  • How lipids improve the per-oral solubility and bioavailability of cannabinoids
  • How to formulate self-emulsifying cannabinoid delivery systems
  • How to analyze emulsion characteristics
Who Should Attend:
  • Formulation scientist
  • Formulator
  • CEO
  • Nutritional formulator
Featured Speakers:

John Tillotson R.Ph., Ph.D.
John Tillotson R.Ph., Ph.D.
Technical Business Director - Canada, Latin America, and India
ABITEC

John Tillotson joined ABITEC Corporation in 2015, and he currently serves as the Pharmaceutical Technical Business Director for Canada, Latin America, and India for ABITEC Corporation.  He is responsible for business development and product technical support in the US, Canada, Latin America, and India.  He has extensive experience in the development of lipid-based drug delivery systems including self-emulsifying drug delivery systems, cannabinoid lipid-based drug delivery systems, co-processed lipid preconcentrates, and topical self-emulsifying formulations.  He has extensive experience in the development of solid oral dosage forms, including the development of multiple direct-compression, drug delivery systems and formulations.  He has developed multiple orally disintegrating excipient systems for both the nutraceutical and pharmaceutical industries, including a patented ODT excipient system.  He has also developed excipient systems for the tableting of lipids.  He has a B.S. in Pharmacy (Ferris State University, MI), and a Ph.D. in Industrial Pharmacy (University of Cincinnati, OH).        
   
Speaker’s Email: jtillotson@abiteccorp.com
Speaker’s LinkedIn: https://www.linkedin.com/in/john-tillotson-730ba4111/
 
Alice Hirschel, PhD
Alice Hirschel, PhD
Technical Business Director
ABITEC

Dr. Alice D. Hirschel has 10 years of research in disease nutrient-interactions and 10 years product and commercial development experience in the food and nutrition industry. She graduated with a BS in Nutritional Sciences from the University of Georgia and a PhD in Nutritional Sciences from the University of Texas at Austin. Dr. Hirschel began formulating supplements as a Product Development Scientist at GNC. She transitioned to Commercial Development with Innophos Nutrition and now, Dr. Hirschel works in technical, commercial and business development, learning to execute sales and marketing strategies with ABITEC Corporation.

Speaker’s Email: ahirschel@abiteccorp.com

For any technical questions please contact Jordan Ramesh: jramesh@mjhlifesciences.com